Dafna D Gladman

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi Prevalence of monoclonal gammopathy among patients with psoriatic arthritis
    Lihi Eder
    Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 39:564-7. 2012
  2. ncbi Inflammatory Spinal Disease in Psoriatic Arthritis: A Report from the GRAPPA 2010 Annual Meeting
    Dafna D Gladman
    Address correspondence to Dr D D Gladman, Toronto Western Hospital, 399 Bathurst Street, 1E410B, Toronto, Ontario M5T 2S8, Canada E mail
    J Rheumatol 39:418-20. 2012
  3. ncbi The Path Forward to Biomarker Discovery in Psoriatic Disease: A Report from the GRAPPA 2010 Annual Meeting
    Dafna D Gladman
    Toronto Western Hospital, 399 Bathurst Street, 1E410B, Toronto, ON M5T 2S8
    J Rheumatol 39:434-6. 2012
  4. ncbi Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study
    Christopher Butt
    Memorial University of Newfoundland, Hospital for Sick Children, Department of Public Health Sciences, University of Toronto, Toronto, Canada
    Arthritis Res Ther 8:R27. 2006
  5. ncbi Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study
    Mandana Nikpour
    University of Toronto Lupus Clinic and the Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada
    Arthritis Res Ther 12:R125. 2010
  6. ncbi Reduced proportions of natural killer T cells are present in the relatives of lupus patients and are associated with autoimmunity
    Joan Wither
    Arthritis Centre of Excellence, Division of Genetics and Development, Toronto Western Hospital Research Institute, University Health Network, Toronto, Ontario, Canada
    Arthritis Res Ther 10:R108. 2008
  7. ncbi Mortality in psoriatic arthritis
    D D Gladman
    University of Toronto, Toronto, Canada
    Clin Exp Rheumatol 26:S62-5. 2008
  8. ncbi Cardiovascular morbidity in psoriatic arthritis
    D D Gladman
    Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada
    Ann Rheum Dis 68:1131-5. 2009
  9. ncbi Clinical and genetic registries in psoriatic disease
    Dafna D Gladman
    University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 35:1458-63. 2008
  10. ncbi Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS)
    D D Gladman
    Toronto Western Research Institute, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    Ann Rheum Dis 68:497-501. 2009

Detail Information

Publications156 found, 100 shown here

  1. ncbi Prevalence of monoclonal gammopathy among patients with psoriatic arthritis
    Lihi Eder
    Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 39:564-7. 2012
    ..There is limited information about the prevalence of monoclonal gammopathy in psoriatic arthritis (PsA). We investigated the prevalence, type, and associated features of monoclonal gammopathy in patients with PsA...
  2. ncbi Inflammatory Spinal Disease in Psoriatic Arthritis: A Report from the GRAPPA 2010 Annual Meeting
    Dafna D Gladman
    Address correspondence to Dr D D Gladman, Toronto Western Hospital, 399 Bathurst Street, 1E410B, Toronto, Ontario M5T 2S8, Canada E mail
    J Rheumatol 39:418-20. 2012
    ....
  3. ncbi The Path Forward to Biomarker Discovery in Psoriatic Disease: A Report from the GRAPPA 2010 Annual Meeting
    Dafna D Gladman
    Toronto Western Hospital, 399 Bathurst Street, 1E410B, Toronto, ON M5T 2S8
    J Rheumatol 39:434-6. 2012
    ..In this overview, we discuss the challenges of the clinical phenotype of PsA and review GRAPPA plans for developing a research program for biomarker discovery...
  4. ncbi Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study
    Christopher Butt
    Memorial University of Newfoundland, Hospital for Sick Children, Department of Public Health Sciences, University of Toronto, Toronto, Canada
    Arthritis Res Ther 8:R27. 2006
    ..Because of the conflicting findings reported regarding the association of PTPN22 with PsA, further studies in other PsA populations are warranted...
  5. ncbi Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study
    Mandana Nikpour
    University of Toronto Lupus Clinic and the Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada
    Arthritis Res Ther 12:R125. 2010
    ..The objective of this study was to describe and quantify variability over time of TC and BP among patients with SLE and to determine their correlates...
  6. ncbi Reduced proportions of natural killer T cells are present in the relatives of lupus patients and are associated with autoimmunity
    Joan Wither
    Arthritis Centre of Excellence, Division of Genetics and Development, Toronto Western Hospital Research Institute, University Health Network, Toronto, Ontario, Canada
    Arthritis Res Ther 10:R108. 2008
    ..Here, we used flow cytometry to investigate whether some of the immune abnormalities that are seen in the peripheral blood lymphocyte population of lupus patients are seen in their first-degree relatives...
  7. ncbi Mortality in psoriatic arthritis
    D D Gladman
    University of Toronto, Toronto, Canada
    Clin Exp Rheumatol 26:S62-5. 2008
    ..Since disease activity is associated with progression of damage, and damage predicts mortality, it is important to treat patients aggressively to prevent these outcomes...
  8. ncbi Cardiovascular morbidity in psoriatic arthritis
    D D Gladman
    Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada
    Ann Rheum Dis 68:1131-5. 2009
    ..Increasing evidence for cardiovascular mortality among patients with psoriasis and psoriatic arthritis (PsA) has accumulated, together with evidence for increased prevalence of risk factors for cardiovascular disease (CVD)...
  9. ncbi Clinical and genetic registries in psoriatic disease
    Dafna D Gladman
    University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 35:1458-63. 2008
    ..Proceedings of these meetings are summarized...
  10. ncbi Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS)
    D D Gladman
    Toronto Western Research Institute, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    Ann Rheum Dis 68:497-501. 2009
    ..To develop and validate a psoriatic arthritis (PsA) screening questionnaire: the Toronto Psoriatic Arthritis Screen (ToPAS)...
  11. ncbi Axial disease in psoriatic arthritis
    Dafna D Gladman
    Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst Street, 1E 410B, Toronto, Ontario, M5T 2S8, Canada
    Curr Rheumatol Rep 9:455-60. 2007
    ..This article reviews the prevalence, clinical and radiologic features, pathogenesis, prognosis, and treatment of psoriatic spondylitis...
  12. ncbi The effect of lupus nephritis on pregnancy outcome and fetal and maternal complications
    Dafna D Gladman
    University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Ontario, Canada
    J Rheumatol 37:754-8. 2010
    ..To evaluate the effect of lupus nephritis on pregnancy with respect to fetal outcome, maternal complications, and lupus activity...
  13. ncbi HLA markers for susceptibility and expression in scleroderma
    Dafna D Gladman
    Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Ontario, Canada
    J Rheumatol 32:1481-7. 2005
    ..Our objective was (1) to determine the role of HLA alleles in the susceptibility to scleroderma; and (2) to determine the role of HLA alleles in various aspects of disease expression...
  14. ncbi Biologic therapy of psoriatic arthritis
    D D Gladman
    Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada
    Reumatismo 59:85-7. 2007
    ..However, not all patients have responded, and the long-term safety of these drugs remains unknown...
  15. ncbi Outcome measures in psoriatic arthritis
    Dafna D Gladman
    University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto, Canada
    J Rheumatol 32:2262-9. 2005
    ..A set of domains to be included in the assessment of patients with PsA was derived, and a research agenda was developed...
  16. ncbi International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis
    Dafna D Gladman
    Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 34:1740-5. 2007
    ..To determine whether the assessments of peripheral joints and enthesitis were reproducible for both AS and PsA with axial disease, and whether dactylitis assessment is reproducible in patients with PsA...
  17. ncbi A novel, disease-specific quality-of-life instrument for patients with SLE
    Dafna D Gladman
    Division of Outcomes and Population Health, Toronto Western Research Institute, Toronto, ON, Canada
    Nat Clin Pract Rheumatol 2:132-3. 2006
  18. ncbi Outcome measures in psoriatic arthritis
    Dafna D Gladman
    The University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 34:1159-66. 2007
    ..This article summarizes these features of PsA as well as current knowledge on the instruments available for the assessment of these domains...
  19. ncbi Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial
    Dafna D Gladman
    University of Toronto, and Toronto Western Hospital, Toronto, Ontario, Canada
    Arthritis Rheum 56:476-88. 2007
    ..To evaluate the efficacy and safety of treatment with adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, over 48 weeks in patients with moderate to severe psoriatic arthritis (PsA)...
  20. ncbi Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial
    D D Gladman
    Toronto Western Hospital, Centre for Prognosis Studies in the Rheumatic Diseases, 1E 410B, 399 Bathurst Street, Toronto, Ontario, Canada M5T 2S8
    Ann Rheum Dis 66:163-8. 2007
    ..To evaluate the effects of adalimumab on patient-reported outcomes of joint-related and skin-related functional impairment, health-related quality of life, fatigue and pain in patients with psoriatic arthritis (PsA)...
  21. ncbi Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases?
    D D Gladman
    Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst Street, 1E 410B, Toronto, Ontario, M5T 2S8, Canada
    Ann Rheum Dis 65:iii22-4. 2006
  22. ncbi International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures
    Dafna D Gladman
    Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 34:1733-9. 2007
    ..To determine whether the axial measures used in primary ankylosing spondylitis (AS) were reproducible for both AS and psoriatic arthritis (PsA) with axial disease...
  23. ncbi Psoriatic arthritis
    Dafna D Gladman
    Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario, Canada
    Dermatol Ther 22:40-55. 2009
    ..New medications, including biologics, have emerged with potential to controlling the inflammation and arresting the progression of joint damage...
  24. ncbi Patient-reported outcome in psoriatic arthritis: a comparison of Web-based versus paper-completed questionnaires
    Heather MacKenzie
    Psoriatic Arthritis Program, University Health Network, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 38:2619-24. 2011
    ....
  25. ncbi The association between smoking and the development of psoriatic arthritis among psoriasis patients
    Lihi Eder
    Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, ON, Canada
    Ann Rheum Dis 71:219-24. 2012
    ..To investigate the association between smoking and psoriatic arthritis (PsA) among patients with psoriasis and its interaction with the HLA-C*06 allele...
  26. ncbi Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?
    Dafna D Gladman
    Correspondence toDr Dafna Gladman, Toronto Western Hospital, 399 Bathurst St, Suite 1E 410B, Toronto, Ontario, Canada, M5T 2S8
    Ann Rheum Dis 70:2152-4. 2011
    ....
  27. ncbi Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis
    Lihi Eder
    Correspondence to Dr Dafna D Gladman, University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst Street, 1E 410B, Toronto M5T 2S8, Canada
    Ann Rheum Dis 71:50-5. 2012
    ..The authors aimed to identify human leucocyte antigen (HLA) alleles that are associated with the development of PsA in patients with psoriasis...
  28. ncbi Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial
    Dafna D Gladman
    Toronto Western Hospital University of Toronto and University Health Network, Toronto, Ontario, Canada
    J Rheumatol 38:1355-62. 2011
    ..To describe the longterm effectiveness and safety of etanercept in Canadian patients with psoriatic arthritis (PsA), treated over 24 months in clinical practice...
  29. ncbi The Spondyloarthritis Research Consortium of Canada registry for spondyloarthritis
    Dafna D Gladman
    Toronto Western Research Institute, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 38:1343-8. 2011
    ..This article describes the SPARCC database and outlines difficulties and possible solutions for maintaining such a database...
  30. ncbi Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future?
    Dafna D Gladman
    Toronto Western Research Institute, Psoriatic Arthritis Program, University Health Network, University of Toronto, Ontario, Canada
    Curr Rheumatol Rep 13:346-52. 2011
    ..It is hoped that an international effort currently on the way will further enhance the contribution of PsA patient registries to address the etiology, pathogenesis, and outcome of this complex disease...
  31. ncbi Informing response criteria for psoriatic arthritis (PsA). II: Further considerations and a proposal--the PsA joint activity index
    Dafna D Gladman
    University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 37:2559-65. 2010
    ..To develop a recommended measure of response for use in psoriatic arthritis (PsA) clinical trials and observational cohort studies reflecting joint involvement...
  32. ncbi Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program
    Dafna D Gladman
    Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, ON M5T 2S8, Canada
    Rheumatology (Oxford) 50:25-31. 2011
    ..We also describe the development of an international collaboration based on this cohort, which will further be used to study the incidence, prevalence and predictive factors for the development of PsA among patients with psoriasis...
  33. ncbi Informing response criteria for psoriatic arthritis. I: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies
    Dafna D Gladman
    Toronto Western Hospital, 399 Bathurst Street, 1E410B, Toronto, Ontario M5T 2S8, Canada
    J Rheumatol 37:1892-7. 2010
    ....
  34. ncbi Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study
    Dafna D Gladman
    Toronto Western Research Institute, 399 Bathurst Street, Room 1E 410B, Toronto, Ontario M5T 2S8, Canada
    J Rheumatol 37:1898-906. 2010
    ..To evaluate the effectiveness and safety of adalimumab in patients with active psoriatic arthritis (PsA) and an inadequate response to prior therapy...
  35. ncbi Pharmacoeconomics of adalimumab for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease
    Dafna D Gladman
    Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, 399 Bathurst St 1E 410B, Toronto, ON M5T 2S8, Canada
    Expert Rev Pharmacoecon Outcomes Res 8:111-25. 2008
    ..Cost-effectiveness data for newer indications of adalimumab, including ankylosing spondylitis and Crohn's disease, are needed. As longer term data for adalimumab become available, the cost-effectiveness data will have greater precision...
  36. ncbi Composite measures in psoriatic arthritis: GRAPPA 2008
    Dafna D Gladman
    University of Toronto, Ontario, Canada
    J Rheumatol 37:453-61. 2010
    ..e., in addition to assessment of peripheral joints, it should include assessment of sacroiliitis, spondylitis, enthesitis, and dactylitis, as well as skin and nail disease...
  37. ncbi Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2008
    Dafna D Gladman
    University of Toronto, Ontario, Canada
    J Rheumatol 37:446-7. 2010
    ..Summaries of those discussions are presented in this supplement...
  38. ncbi Psoriatic arthritis from Wright's era until today
    Dafna D Gladman
    Toronto Western Research Institute, Toronto Western Hospital, Toronto, Ontario M5T 2S8, Canada
    J Rheumatol Suppl 83:4-8. 2009
    ..Since other presentations focus on pathogenesis and treatment, this article emphasizes the clinical features and prognosis, as well as development of outcome measures...
  39. ncbi Spondyloarthropathies: Targeted therapy for psoriatic arthritis
    Dafna D Gladman
    University of Toronto and Toronto Western Research Institute, Toronto, ON, Canada
    Nat Rev Rheumatol 5:241-2. 2009
    ..Tumor necrosis factor inhibitors are an effective treatment for psoriatic arthritis, but no single agent is effective in all patients. Novel therapies that target other cytokines have now been tested, with encouraging results...
  40. ncbi Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review
    Dafna D Gladman
    University of Toronto, Toronto Western Research Institute, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto, Ontario, Canada
    Drugs 65:1223-38. 2005
    ..Most of these medications have been found to be effective in both psoriasis and PsA. Recent randomised controlled trials suggest that at least anti-TNF agents may help prevent progression of joint destruction...
  41. ncbi The nature and outcome of infection in systemic lupus erythematosus
    D D Gladman
    The University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Ontario, Canada
    Lupus 11:234-9. 2002
    ..Until new medications which will control disease activity without predisposing to infection are developed, careful titration of steroids and cytotoxic drugs to control disease activity will remain crucial...
  42. ncbi Psoriatic arthritis
    D D Gladman
    University of Toronto Psoriatic Arthritis Clinic and Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada
    Expert Opin Investig Drugs 9:1511-22. 2000
    ..Any treatment for the arthritis must also help the skin. Greater understanding of psoriatic arthritis, its pathogenesis and natural history is required if we are to target these exciting but expensive therapies effectively...
  43. ncbi Longitudinal cohort studies
    Dafna D Gladman
    University of Toronto, Toronto Western Research Institute, Psoriatic Arthritis Program UHN, Toronto, Canada
    J Rheumatol Suppl 72:30-2. 2005
    ..Analysis issues are highlighted and proposed mechanisms offered for keeping patients involved to ensure complete followup is maintained...
  44. ncbi Psoriatic arthritis
    Dafna D Gladman
    Center for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario
    Dermatol Ther 17:350-63. 2004
    ..Traditional medications have not been effective in preventing the progression of joint damage. New medications, including biologics, have emerged with the potential to control the inflammation and arrest the progression of joint damage...
  45. ncbi The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada
    Dafna D Gladman
    The Psoriatic Arthritis Program, University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 31:1126-31. 2004
    ..To evaluate whether rheumatologists experienced in psoriatic arthritis (PsA) assess peripheral and axial involvement in the same way and to consider core clinical measurements that should be included in clinical trials in PsA...
  46. ncbi Current concepts in psoriatic arthritis
    Dafna D Gladman
    University of Toronto, Ontario, Canada
    Curr Opin Rheumatol 14:361-6. 2002
    ..This review summarizes articles written about psoriatic arthritis in the past year. It concentrates on clinical and epidemiologic issues, pathogenesis and treatment, and updates the reader regarding new concepts in psoriatic arthritis...
  47. ncbi HLA is a candidate region for psoriatic arthritis. evidence for excessive HLA sharing in sibling pairs
    Dafna D Gladman
    Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Hum Immunol 64:887-9. 2003
    ..04); whereas the haplotype sharing for the Ps affected sibling pairs was 12, 26, and 10, respectively (p = 0.38). In conclusion, the human leukocyte antigen region on chromosome 6p is implicated as one of the candidate regions in PsA...
  48. ncbi Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus
    D D Gladman
    University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Ontario, Canada
    J Rheumatol 28:2226-9. 2001
    ....
  49. ncbi HLA-DRB1*04 alleles in psoriatic arthritis: comparison with rheumatoid arthritis and healthy controls
    D D Gladman
    University of Toronto, Toronto, Canada
    Hum Immunol 62:1239-44. 2001
    ....
  50. ncbi Established criteria for disease controlling drugs in ankylosing spondylitis
    D D Gladman
    Centre for Prognosis Studies, Toronto Western Hospital, ECW 5-034B, Toronto, ON, Canada
    Ann Rheum Dis 62:793-4. 2003
  51. ncbi Effectiveness of psoriatic arthritis therapies
    Dafna D Gladman
    Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    Semin Arthritis Rheum 33:29-37. 2003
    ..To review the effectiveness of systemic therapies for psoriatic arthritis (PsA)...
  52. ncbi Psoriatic arthritis clinical registries and genomics
    D D Gladman
    University of Toronto, Toronto Western Research Institute, Psoriatic Arthritis Program, University Health Network, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Ontario M5T 2S8, Canada
    Ann Rheum Dis 64:ii103-5. 2005
    ..Careful collection and analysis of patient data through collaborative efforts will likely advance our knowledge of pathogenesis and provide new and much needed insights about the course and prognosis of the disease...
  53. ncbi Clinical aspects of the spondyloarthropathies
    D D Gladman
    University of Toronto, The Centre for Prognosis Studies in the Rheumatic Diseases, The Toronto Hospital, Ontario, Canada
    Am J Med Sci 316:234-8. 1998
    ..Differences in response to medications and in prognosis are such that it is important to make the correct diagnosis in the individual patient...
  54. ncbi Accurately describing changes in disease activity in Systemic Lupus Erythematosus
    D D Gladman
    The University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Ontario, Canada
    J Rheumatol 27:377-9. 2000
    ..To determine whether Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores correlate with the clinician's impression of level of disease activity...
  55. ncbi Introduction/overview on clinical registries
    D D Gladman
    University of Toronto Western Research Institute, Psoriatic Arthritis Program, Toronto Western Hospital, Ontario M5T 2S8, Canada
    Ann Rheum Dis 64:ii101-2. 2005
  56. ncbi Consensus exercise on domains in psoriatic arthritis
    D D Gladman
    University of Toronto, Toronto Western Research Institute, Psoriatic Arthritis Program, University Health Network, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Ontario M5T 2S8, Canada
    Ann Rheum Dis 64:ii113-4. 2005
    ..These domains require further refining, and instruments to measure the items need to be developed...
  57. ncbi OMERACT 7 psoriatic arthritis workshop: synopsis
    D D Gladman
    University of Toronto, Western Research Institute, Psoriatic Arthritis Program, Toronto Western Hospital, Ontario M5T 2S8, Canada
    Ann Rheum Dis 64:ii115-6. 2005
    ....
  58. ncbi Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus
    Murray B Urowitz
    Toronto Western Hospital, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, Canada
    J Rheumatol 35:2152-8. 2008
    ..We examined changes in mortality and other outcomes over time in a large SLE cohort...
  59. ncbi Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis
    Janice A Husted
    University of Waterloo, Waterloo, Ontario, Canada
    Arthritis Care Res (Hoboken) 63:1729-35. 2011
    ..To determine whether the presence of psoriatic arthritis (PsA) is associated with greater comorbidity, in particular cardiovascular morbidity, compared to psoriasis without arthritis...
  60. ncbi Glomerular filtration rate predicts arterial events in women with systemic lupus erythematosus
    Wendy Zhang
    Arthritis Centre of Excellence, Toronto Western Hospital, Toronto, ON M5T 2S8, Canada
    Rheumatology (Oxford) 50:799-805. 2011
    ..To determine whether renal function predicts the development of cardiovascular disease and other arterial vascular events in patients with SLE...
  61. ncbi Clinical and serologic factors associated with lupus pleuritis
    Shikha Mittoo
    Department of Medicine, University of Manitoba, Manitoba, Canada
    J Rheumatol 37:747-53. 2010
    ..Pleuritis is a common manifestation and independent predictor of mortality in systemic lupus erythematosus (SLE). We examined the prevalence of pleuritis and factors associated with pleuritis in a multicenter Canadian SLE cohort...
  62. ncbi Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT
    Dafna D Gladman
    University of Toronto, 399 Bathurst Street, Room 1E 410B, Toronto, Ontario M5T 2S8, Canada
    Arthritis Res Ther 12:R113. 2010
    ..To identify independent predictors of radiographic progression in psoriatic arthritis (PsA) for patients treated with adalimumab or placebo in the Adalimumab Effectiveness in PsA Trial (ADEPT)...
  63. ncbi Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone
    Cheryl F Rosen
    Toronto Western Hospital, Toronto, ON M5T 2S8, Canada
    Rheumatology (Oxford) 51:571-6. 2012
    ..Both conditions have a significant impact on quality of life (QoL). Our objective was to test the hypothesis that people with PsA have poorer QoL than patients with PsC because of the added burden of arthritis, age and comorbidities...
  64. ncbi Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors
    Murray B Urowitz
    University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 34:70-5. 2007
    ....
  65. ncbi Prolonged remission in systemic lupus erythematosus
    Murray B Urowitz
    University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University Health Network, Ontario, Canada
    J Rheumatol 32:1467-72. 2005
    ..To also determine the frequency of remission utilizing less restrictive definitions, such as allowing shorter period of disease quiescence, persistence of serological activity, or treatment in the absence of clinical disease...
  66. ncbi Clinically active serologically quiescent systemic lupus erythematosus
    Dafna D Gladman
    University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst Street, EC 5-034, Toronto, Ontario, Canada M5T 2S8
    J Rheumatol 30:1960-2. 2003
    ..The minority have discordance between clinical and serological status, and are either SACQ or CASQ. Therefore, monitoring both clinical and serological features in patients with SLE is important...
  67. ncbi Incidence of arthritis in a prospective cohort of psoriasis patients
    Lihi Eder
    University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases 1E 410B, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario, Canada M5T 2S8
    Arthritis Care Res (Hoboken) 63:619-22. 2011
    ..There are limited data regarding the incidence of PsA in patients with psoriasis. We aimed to determine the incidence of PsA among a prospective cohort of psoriasis patients...
  68. ncbi Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort
    Lihi Eder
    Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, ON, Canada
    Rheumatology (Oxford) 49:1361-6. 2010
    ..To determine predictors and time to response to treatment with TNF-alpha blockers in patients with PsA in a longitudinal observational cohort...
  69. ncbi Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus
    Mandana Nikpour
    University of Toronto Lupus Clinic and the Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 36:288-94. 2009
    ..In this prospective cohort study we investigated whether myocardial perfusion defects in SLE are predictive of CAD events, independently of traditional Framingham risk factors...
  70. ncbi A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: Does the effect change over time?
    Janice A Husted
    University of Waterloo, Waterloo, Ontario, Canada
    Arthritis Rheum 56:840-9. 2007
    ..To investigate whether there are differential effects of disease activity and damage on physical functioning as measured by the Health Assessment Questionnaire (HAQ) over the course of psoriatic arthritis (PsA)...
  71. ncbi Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis
    Vinod Chandran
    University of Toronto, Toronto, Canada
    J Rheumatol 37:1508-12. 2010
    ..To determine the association between folate pathway gene polymorphisms and the effectiveness, toxicity, and drug survival of methotrexate (MTX) in psoriatic arthritis (PsA)...
  72. ncbi Serum albumin as a marker for disease activity in patients with systemic lupus erythematosus
    Jonathan Yip
    Division of Health Care and Outcome Research, Toronto Western Research Institute, Toronto, Ontario, Canada
    J Rheumatol 37:1667-72. 2010
    ..There is currently no clinical "gold standard" in the assessment of disease activity in SLE...
  73. ncbi Accrual of organ damage over time in patients with systemic lupus erythematosus
    Dafna D Gladman
    University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst Street, EC 5-034, Toronto, Ontario, Canada M5T 2S8
    J Rheumatol 30:1955-9. 2003
    ..CONCLUSION: While the overall accrual of damage is gradual, the specific systems demonstrate varying patterns of damage accrual...
  74. ncbi Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis
    Vinod Chandran
    Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Ontario, Canada
    J Rheumatol 37:809-15. 2010
    ..Axial involvement is an important manifestation of psoriatic arthritis (PsA). We aimed to identify risk factors associated with the presence of axial PsA (AxPsA) in patients with PsA...
  75. ncbi Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus
    Sindhu R Johnson
    Division of Rheumatology, Centre for Prognostic Studies in the Rheumatic Diseases, University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 33:1990-5. 2006
    ..African-Canadians had a higher prevalence of renal disease and damage. Further investigation into other determinants such as genetic predisposition, treatment, and cultural perceptions is needed...
  76. ncbi High resolution mapping in the major histocompatibility complex region identifies multiple independent novel loci for psoriatic arthritis
    Proton Rahman
    Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, 1E 410B, Toronto, Ontario M5T 2S8, Canada
    Ann Rheum Dis 70:690-4. 2011
    ..The study primary objective was to identify single nucleotide polymorphisms (SNPs) independent of known human leucocyte antigen (HLA) alleles within the MHC region that are associated with PsA using a high-density SNP map...
  77. ncbi Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time
    Dominique Ibanez
    University of Toronto Lupus Clinic and Centre for Prognosis Studies in the Diseases, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 38:60-3. 2011
    ..adjusted mean Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; AMS) measures lupus disease activity over time. Our aim was to determine optimal visit frequency for calculating AMS...
  78. ncbi Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis
    Lynne Cresswell
    MRC Biostatistics Unit, Cambridge, UK
    Ann Rheum Dis 70:305-8. 2011
    ..The aim of this study was to identify key predictors of damage to individual joints in the hands and feet of patients with PsA, in particular those that capture previous activity...
  79. ncbi Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis
    Zahi Touma
    University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 38:69-78. 2011
    ..to systematically review the efficacy and safety of mycophenolic acid and mycophenolate mofetil (MMF) compared to cyclophosphamide (CYC) for the induction treatment of lupus nephritis (LN)...
  80. ncbi Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort
    Vinod Chandran
    University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 35:469-71. 2008
    ..Our aim was to determine if MTX is being used earlier in the course of PsA and in a higher dose and whether that has led to improved outcomes...
  81. ncbi IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients
    Lihi Eder
    Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto Psoriatic Arthritis Clinic, Toronto Western Hospital, Toronto, Ontario, Canada
    Ann Rheum Dis 70:1594-8. 2011
    ..To study the association between smoking and IL13 gene polymorphisms with psoriatic arthritis (PsA) and psoriasis...
  82. ncbi Repair of radiographic joint damage following treatment with etanercept in psoriatic arthritis is demonstrable by 3 radiographic methods
    Lihi Eder
    Centre for Prognosis Studies in the Rheumatic Diseases, 1E 410B, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario M5T 2S8
    J Rheumatol 38:1066-70. 2011
    ..We describe a patient with PsA with severe radiographic damage that improved significantly following treatment with etanercept. The improvement was documented by several methods of radiographic assessment...
  83. ncbi Systemic lupus erythematosus disease activity index 2000 responder index-50: a reliable index for measuring improvement in disease activity
    Zahi Touma
    Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario, Canada
    J Rheumatol 38:868-73. 2011
    ....
  84. ncbi Toronto Psoriatic Arthritis Screening (ToPAS) questionnaire: a report from the GRAPPA 2009 annual meeting
    Vinod Chandran
    Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 38:546-7. 2011
    ..Results of a comparison of the ToPAS questionnaire with the Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire were also presented. Modification and further validation of the ToPAS are under way...
  85. ncbi Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients
    M Feletar
    University of Toronto Psoriatic Arthritis Clinic, Toronto Western Hospital, Toronto, Canada
    Ann Rheum Dis 63:156-61. 2004
    ..5x normal, occurred in four patients. CONCLUSION: In refractory PsA, infliximab led to a marked improvement in psoriasis but modest response in joint disease. Toxicity and rate of treatment termination was high...
  86. ncbi Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis
    J A Husted
    Department of Health Studies and Gerontology, University of Waterloo, Ontario, Canada
    Arthritis Rheum 45:151-8. 2001
    ..Further, it appeared that there may be unique disabilities associated with the psoriasis dimension of PsA...
  87. ncbi Role of specialty care in the management of patients with systemic lupus erythematosus
    Murray B Urowitz
    University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Ontario, Canada
    J Rheumatol 29:1207-10. 2002
    ..To determine the role of rheumatologists in the management of systemic lupus erythematosus (SLE)...
  88. ncbi The effect of menopause on disease activity in systemic lupus erythematosus
    Murray B Urowitz
    University of Toronto Lupus Clinic and Toronto Western Hospital, Edith Cavell Wing, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada
    J Rheumatol 33:2192-8. 2006
    ..To determine the effect of menopause on disease activity and course of systemic lupus erythematosus (SLE)...
  89. ncbi Systemic lupus erythematosus disease activity index 2000
    Dafna D Gladman
    The University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Ontario, Canada
    J Rheumatol 29:288-91. 2002
    ..CONCLUSION: SLEDAI-2K, which allows for persistent activity in rash, mucous membranes, alopecia, and proteinuria, is suitable for use in clinical trials and studies of prognosis in SLE...
  90. ncbi Contributions of observational cohort studies in systemic lupus erythematosus: the university of toronto lupus clinic experience
    Murray B Urowitz
    University of Toronto, Toronto, ON, Canada
    Rheum Dis Clin North Am 31:211-21, v. 2005
    ..This article uses the University of Toronto Lupus Cohort to illustrate the benefits of observational cohort studies in generating important new knowledge in chronic disease such as systemic lupus erythematosus...
  91. ncbi Axial psoriatic arthritis: update on a longterm prospective study
    Vinod Chandran
    Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 36:2744-50. 2009
    ..To evaluate changes in symptoms, spinal mobility, and radiographic features in patients with axial psoriatic arthritis (AxPsA)...
  92. ncbi Relationship between spinal mobility and radiographic damage in ankylosing spondylitis and psoriatic spondylitis: a comparative analysis
    Vinod Chandran
    University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 34:2463-5. 2007
    ..To correlate measures of spinal mobility used in the assessment of spondyloarthritis with radiographic severity, and to compare ankylosing spondylitis (AS) and psoriatic spondylitis (Ps-Sp) in this clinical-radiographic correlation...
  93. ncbi Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide
    Murray B Urowitz
    University of Toronto Lupus Clinic, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 34:1491-6. 2007
    ..To assess outcomes in patients with lupus nephritis treated with immunosuppressives compared to those treated with cyclophosphamide in a cohort study and in a matched cohort study...
  94. ncbi Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials
    Zahi Touma
    University of Toronto Lupus Clinic, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
    J Rheumatol 38:2395-9. 2011
    ..Also, to determine whether the SRI-50 will enhance the ability of SRI in detecting responders...
  95. ncbi Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus
    Mandana Nikpour
    University of Toronto Lupus Clinic and the Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada
    Arthritis Rheum 61:1152-8. 2009
    ..We sought to elucidate the frequency and determinants of flare and PAD...
  96. ncbi Quality of life over time in patients with systemic lupus erythematosus
    Bindee Kuriya
    University of Toronto Lupus Clinic Toronto, Ontario, Canada
    Arthritis Rheum 59:181-5. 2008
    ..To determine whether quality of life in patients with systemic lupus erythematosus (SLE) measured by the Short Form 36 (SF-36) changes over time and which patient- and disease-related factors influence such change...
  97. ncbi Association of interleukin 23 receptor variants with psoriatic arthritis
    Proton Rahman
    Department of Medicine, Memorial University, 154 Le Marchant Road, St John s, NL, Canada, A1C 5B8
    J Rheumatol 36:137-40. 2009
    ..Given the interplay between psoriasis and PsA, we examined the association of IL-23R variants in 2 independent Canadian Caucasian cohorts of patients with psoriatic arthritis (PsA)...
  98. ncbi The SLICC inception cohort for atherosclerosis
    Murray B Urowitz
    University of Toronto Lupus Clinic, Toronto Western Hospital, Room 1E 409, 399 Bathurst Street, Toronto, ON, Canada
    Curr Rheumatol Rep 10:281-5. 2008
    ..Additional studies using this cohort are ongoing...
  99. ncbi Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus?
    Zahi Touma
    Centre for Prognosis Studies in the Rheumatic Diseases, Room 1E 409, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada
    J Rheumatol 38:1898-905. 2011
    ....